NEWS
View news from our Featured Companies.
Shuttle Pharmaceuticals Commences Trading on Nasdaq Under Ticker Symbol “SHPH”
Shuttle Pharma's platform of sensitizers are designed to address the urgent clinical need to improve the outcomes of cancer patients treated with radiation therapy while reducing side effects ROCKVILLE, Md., Aug. 31, 2022 -- Shuttle Pharmaceuticals Holdings, Inc....
Shuttle Pharmaceuticals Announces Pricing of Initial Public Offering
ROCKVILLE, Md., Aug. 30, 2022 -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the outcomes of cancer patients treated with radiation therapy (RT) while reducing side...
Fei Chen to Become LiqTech President and CEO on September 12, 2022
BALLERUP, Denmark, Aug. 30, 2022 -- LiqTech International, Inc. (NASDAQ: LIQT), a clean technology company that manufactures and markets highly specialized filtration products and systems, today announced that the Company's newly appointed President and Chief...
PolyPid Announces Presentation at the 2022 Military Health System Research Symposium
Efficacy Data of D-PLEX100 in reduction of Surgical Site Infection in Surgical Trauma Injuries will be Presented During a Podium Presentation PETACH TIKVA, Israel, Aug. 30, 2022 -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), a late-stage biopharma...
Zoomd Reports 2Q2022 Financial Results. Revenues Increased 45% YOY, Representing the 6th YOY Consecutive Quarter of Growth
Conference call will be held on August 30, 2022 at 11AM ET VANCOUVER, BC, Aug. 29, 2022 /CNW/ -- Zoomd Technologies Ltd. (TSXV: ZOMD) (OTC: ZMDTF) and its wholly-owned subsidiary Zoomd Ltd. (collectively, "Zoomd" or the "Company"), the marketing technology (MarTech)...
SenesTech Announces Distribution of Series C Preferred Stock to Holders of its Common Stock
Intended to Facilitate a Reverse Stock Split, if Necessary PHOENIX, Aug. 26, 2022 -- SenesTech, Inc. (NASDAQ: SNES, "SenesTech" or the "Company") (www.senestech.com), the rodent fertility control experts and inventors of the only EPA registered contraceptive for male...
INVOcell Launched in Malaysia by Advanced Reproductive Centre, Hospital Canselor Tuanku Muhriz
SARASOTA, Fla., Aug. 25, 2022 -- INVO Bioscience, Inc. (Nasdaq: INVO), a commercial-stage fertility company focused on expanding access to advanced treatment worldwide with its INVOcell ® medical device and the intravaginal culture ("IVC") procedure it enables,...
ARIANNE PHOSPHATE REPORTS CORPORATE AND FINANCIAL RESULTS FOR SECOND QUARTER 2022
DAN: TSX-V (Canada)JE9N: FSE (Germany)DRRSF: OTC (USA) SAGUENAY, QC, Aug. 24, 2022 /CNW/ - Arianne Phosphate (the "Company" or "Arianne") (TSXV: DAN) (OTC: DRRSF) (FRANKFURT: JE9N), a development-stage phosphate mining company, advancing its Lac à Paul project in...
Zoomd to Report Second Quarter 2022 Financial Results on August 29, 2022
Conference call to be conducted on August 30, 2022 at 11 a.m. ET. VANCOUVER, BC, Aug. 24, 2022 /CNW/ -- Zoomd Technologies Ltd. (TSXV: ZOMD) (OTC: ZMDTF) and its wholly-owned subsidiary Zoomd Ltd. (collectively, "Zoomd" or the "Company"), the marketing technology...
Aytu BioPharma to Participate in September 2022 Investor Conferences
ENGLEWOOD, CO / August 24, 2022 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, with a development pipeline addressing rare, pediatric-onset disorders, today announced that Aytu's management team will...
Aytu BioPharma Announces Issuance of Its First Patent for AR101/Enzastaurin
First Issued U.S. Patent Covers Methods of Treating a Broad Range of Inherited Aortic Aneurism and Related Conditions Including Vascular Ehlers-Danlos SyndromeMultiple Patent Families Filed in Key Global MarketsENGLEWOOD, CO / August 16, 2022 / Aytu BioPharma, Inc....
Reviva Pharmaceuticals Holdings, Inc. Reports Second Quarter 2022 Financial Results and Recent Business Highlights
- Enrollment on pace for ongoing pivotal Phase 3 RECOVER trial - - Topline data for RECOVER evaluating brilaroxazine for schizophrenia expected in mid-2023 - - $19.4 Million in Cash as of June 30, 2022 - CUPERTINO, Calif., Aug. 15, 2022 -- Reviva Pharmaceuticals...
INVO Bioscience Reports Second Quarter 2022 Financial Results
Company to Host Conference Call Today at 4:30pm ET SARASOTA, Fla., Aug. 15, 2022 -- INVO Bioscience, Inc. (Nasdaq: INVO) ("INVO" or the "Company"), a commercial-stage fertility company focused on expanding access to advanced treatment worldwide with its INVOcell®...
Aytu BioPharma Announces Closing of $10.0 Million Registered Public Offering
ENGLEWOOD, CO / August 15, 2022 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on developing and commercializing novel therapeutics, today announced the closing of its previously announced underwritten public offering...
Thorne Research, Inc. Loses Patent Challenge Decision, Upholding ChromaDex’s Intellectual Property Held Under Exclusive License From Dartmouth College
The "807" patent held under exclusive license covers compositions comprising NAD+ precursor nicotinamide riboside LOS ANGELES - ChromaDex Corp. (NASDAQ:CDXC) ("the Company") a global bioscience company dedicated to healthy aging, announced the U.S. Patent &...
Kiora Pharmaceuticals Reports First Half 2022 Business Update and Financial Results
Salt Lake City, Utah--(August 12, 2022) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), ("Kiora" or the "Company") today is reporting financial results for the three and six months ended June 30, 2022."In the first half, we continued to advance three core programs...
ImmuCell Announces Unaudited Financial Results for the Quarter Ended June 30, 2022
PORTLAND, Maine, Aug. 11, 2022 -- ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity of dairy...
SenesTech Announces Record Second Quarter 2022 Product Sales
Sales up 73% year-over-year and up 42% sequentially PHOENIX, Aug. 11, 2022 -- SenesTech, Inc. (NASDAQ: SNES, "SenesTech" or the "Company"), (www.senestech.com) the rodent fertility control experts and inventors of the only EPA registered contraceptive for male and...
ContraPest® Shows Dramatic Success in Zoo Deployments
PHOENIX, Aug. 11, 2022 -- SenesTech, Inc. (NASDAQ: SNES, "SenesTech" or the "Company"), (www.senestech.com) the rodent fertility control experts and inventors of the only EPA registered contraceptive for male and female rats, ContraPest, today released further...
Dr. Anne Peters Joins the Modular Medical Advisory Board
Dr. Peters, a prominent diabetes clinician and clinical researcher, is a leading voice in the fight to bring diabetes technology and therapeutics to under-resourced communitiesSAN DIEGO, CA / August 11, 2022 / Modular Medical, Inc. (the "Company" or "Modular...
LiqTech International Announces Second Quarter 2022 Financial Results
BALLERUP, Denmark, Aug. 11, 2022 -- LiqTech International, Inc. (NASDAQ: LIQT) ("LiqTech"), a clean technology company that manufactures and markets highly specialized filtration technologies, today announced its financial results for the second quarter of 2022. Q2...
Mogo Reports Second Quarter 2022 Financial Results
Q2 revenue of $17.3 million, up 27% year over year Member base increases 18% year over year to 2.0 million During the quarter, Mogo implemented cost saving initiatives to accelerate path to profitability Ended quarter with cash, digital assets & investments of...
ChromaDex Corporation Reports Second Quarter 2022 Financial Results
Total net sales of $16.7 million for the three months ended June 30, 2022 with $14.5 million from Tru Niagen® and gross margin of 60.0% for the quarter LOS ANGELES - ChromaDex Corp. (NASDAQ:CDXC) today announced financial results for the second quarter of 2022....
PolyPid Provides Corporate Update and Reports Second Quarter 2022 Financial Results
Signed Exclusive Licensing Agreement for Commercialization of D-PLEX100 in Europe for Potentially Over $110 Million in Upfront and Milestone Payments, Plus Royalties on Net SalesIndependent Data Safety Monitoring Board Recommended Concluding Phase 3 SHIELD I Trial of...
Aytu BioPharma Announces Pricing of Public Offering
ENGLEWOOD, CO / August 9, 2022 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on developing and commercializing novel therapeutics, today announced the pricing of its underwritten public offering of (i) 21,505,814...